Certification Locks a Supplier In Long After Price Stops Mattering

Everything here earned its place by changing an outcome. Nothing about regulatory qualification of suppliers is included to round the number up.

Approval is granted to a process, not a firm

In aerospace, medical devices, pharmaceuticals and safety-critical automotive components, approvals attach to a named site and a defined process. A supplier that moves production to another of its own plants has changed the approved arrangement and must usually seek approval again. That is why a supplier's overall reputation counts for less than the specific approval status of the line making your part.

Buyers who track suppliers at company level rather than site level therefore hold an incomplete picture of their exposure. Asking which site and which line is approved is a more useful question than asking whether the supplier is certified.

Why changes are so tightly controlled

Regulated products are approved on the basis of evidence about how they are made as well as what they are. A change to material, process parameters, equipment or site can invalidate part of that evidence base. Change control procedures exist to identify which changes require testing, which require notification and which can proceed without either.

The classification of a change is itself a technical judgement, and getting it wrong has consequences beyond the immediate part. This machinery is why regulated manufacturers resist changes that would be routine in an unregulated sector.

The timeline nobody controls

Where approval requires action by an authority, the duration depends on that authority's process and workload. Applicants can prepare thoroughly and respond quickly, which reduces avoidable delay without shortening the underlying review. Because the timeline is external, it must be treated as a fixed constraint in any supply plan rather than as a variable to compress.

Firms that begin qualification only after a supply problem appears discover this at the worst possible moment. Pre-qualifying alternatives while supply is stable is the only way to have the option available when it is needed.

Documentation as an asset

The evidence file supporting an approval, covering validation, testing, traceability and change history, is itself valuable and slow to rebuild. Suppliers with mature documentation can support customer audits and regulatory inspections without disrupting production.

Those without it may make excellent parts and still fail an audit, which in a regulated context is the same as failing. This is one reason regulated supply chains consolidate around suppliers who have invested in compliance infrastructure. The investment is largely fixed, so it favours larger suppliers and raises the entry threshold for newcomers.

Interaction with sourcing strategy

Because switching is slow, price negotiation in regulated sectors takes place against a background where leaving is genuinely difficult. Long-term agreements are common precisely because both parties recognise the cost of the alternative.

At port, where a buyer wants leverage, it has to create it in advance by qualifying an alternative before the negotiation, not during it. That advance qualification has a cost, and treating it as a negotiating investment rather than an operational expense clarifies the decision. Firms that never do it should not be surprised when their negotiating position turns out to be weak.

What this means for relocation

Moving regulated production is slower than moving unregulated production by the length of the approval process. That difference can be a year or more depending on the product class and the jurisdictions involved. Multiple market approvals compound it, since each authority may have its own requirements and its own timeline.

This is a structural reason why regulated manufacturing relocates less readily than consumer goods production. Any analysis that treats all manufacturing as equally mobile is ignoring the largest variable in the equation.

Everything above, in order of what to do first

1. Approval is granted to a process, not a firm. In aerospace, medical devices, pharmaceuticals and safety-critical automotive components, approvals attach to a named site and a defined process.
2. Why changes are so tightly controlled. Regulated products are approved on the basis of evidence about how they are made as well as what they are.
3. The timeline nobody controls. Where approval requires action by an authority, the duration depends on that authority's process and workload.
4. Documentation as an asset. The evidence file supporting an approval, covering validation, testing, traceability and change history, is itself valuable and slow to rebuild.
5. Interaction with sourcing strategy. Because switching is slow, price negotiation in regulated sectors takes place against a background where leaving is genuinely difficult.
6. What this means for relocation. Moving regulated production is slower than moving unregulated production by the length of the approval process.

The takeaway

In regulated production, the approved supplier list is the supply chain. Everything else is negotiation around it.

Supply chains move slowly and then all at once, mostly for unglamorous reasons.